Conolidine’s analgesic effects stem from its conversation with non-opioid pain pathways. Unlike opioids, which bind to µ-opioid receptors within the central anxious procedure, conolidine modulates alternate molecular targets. A Science Advances study found that conolidine interacts With all the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide availability. By https://lloydu086rvx8.azzablog.com/profile